Curis, Inc. (CRIS): Price and Financial Metrics


Curis, Inc. (CRIS): $16.27

6.44 (+65.51%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CRIS to Watchlist
Sign Up

Industry: Biotech


Ranked

of 495

in industry

CRIS POWR Grades


  • CRIS scores best on the Growth dimension, with a Growth rank ahead of 74.31% of US stocks.
  • The strongest trend for CRIS is in Momentum, which has been heading down over the past 200 days.
  • CRIS ranks lowest in Momentum; there it ranks in the 13th percentile.

CRIS Stock Summary

  • CRIS's price/sales ratio is 137.41; that's higher than the P/S ratio of 97.14% of US stocks.
  • With a year-over-year growth in debt of 4,515.66%, Curis Inc's debt growth rate surpasses 99.55% of about US stocks.
  • The volatility of Curis Inc's share price is greater than that of 97.98% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Curis Inc are MLSS, EFSC, HHR, ICLK, and BWB.
  • CRIS's SEC filings can be seen here. And to visit Curis Inc's official web site, go to www.curis.com.

CRIS Price Target

For more insight on analysts targets of CRIS, see our CRIS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $17.20 Average Broker Recommendation 1.5 (Moderate Buy)

CRIS Stock Price Chart Interactive Chart >

Price chart for CRIS

CRIS Price/Volume Stats

Current price $16.27 52-week high $17.40
Prev. close $9.83 52-week low $0.72
Day low $9.08 Volume 60,062,199
Day high $17.40 Avg. volume 2,605,696
50-day MA $10.94 Dividend yield N/A
200-day MA $6.02 Market Cap 1.49B

Curis, Inc. (CRIS) Company Bio


Curis, Inc. engages in the discovery and development of drug candidates for the treatment of human cancers. The company was founded in 2000 and is based in Lexington, Massachusetts.


CRIS Latest News Stream


Event/Time News Detail
Loading, please wait...

CRIS Latest Social Stream


Loading social stream, please wait...

View Full CRIS Social Stream

Latest CRIS News From Around the Web

Below are the latest news stories about Curis Inc that investors may wish to consider to help them evaluate CRIS as an investment opportunity.

Curis to Release First Quarter 2021 Financial Results and Hold Conference Call on May 12, 2021

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its first quarter 2021 financial results on Wednesday, May 12, 2021, after the close of US markets. Management will host a conference call on the same day at 4:30 pm ET.

Yahoo | May 5, 2021

Will Curis (CRIS) Report Negative Q1 Earnings? What You Should Know

Curis (CRIS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | May 4, 2021

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on April 1, 2021, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 167,300 shares of Curis common stock to five new employees, with a grant date of April 1, 2021 (the "Q2 2021 Inducement Grants").

Yahoo | April 7, 2021

Point72 Asset Management established new holdings in Curis Inc

https://www.investing.com/news/stock-market-news/point72-asset-management-established-new-holdings-in-curis-inc-2464353

Investing.com | April 1, 2021

Benzinga's Top Ratings Upgrades, Downgrades For March 25, 2021

Upgrades According to Sidoti & Co., the prior rating for QAD Inc (NASDAQ:QADA) was changed from Neutral to Buy. For the fourth quarter, QAD had an EPS of $0.39, compared to year-ago quarter EPS of $0.02. At the moment, the stock has a 52-week-high of $76.11 and a 52-week-low of $34.06. QAD closed at $59.98 at the end of the last trading period. According to Loop Capital, the prior rating for Carlisle Companies Inc (NYSE:CSL) was changed from Hold to Buy. Carlisle Companies earned $1.57 in the fourth quarter, compared to $1.81 in the year-ago quarter. The current stock performance of Carlisle Companies shows a 52-week-high of $161.54 and a 52-week-low of $97.55. Moreover, at the end of the last trading period, the closing price was at $155.88. For Vail Resorts Inc (NYSE:MTN), B of A Secu...

Yahoo | March 25, 2021

Read More 'CRIS' Stories Here

CRIS Price Returns

1-mo 43.10%
3-mo 50.65%
6-mo 1,222.76%
1-year 2,046.44%
3-year 437.85%
5-year 93.69%
YTD 98.66%
2020 381.76%
2019 146.38%
2018 -80.29%
2017 -77.27%
2016 5.84%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.762 seconds.